finance.yahoo.com ·
Biotech Fund Sells 44 5
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedInsider selling by a biotech fund reduces its exposure to Erasca, a clinical-stage oncology company. The sale is a portfolio rebalancing event, not a fundamental change in Erasca's business or drug pipeline. No direct commercial mechanism such as supply shortage, demand spike, or margin squeeze is identified. The impact is limited to the single company's stock sentiment.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Paradigm Biocapital sold 3,766,393 shares of Erasca (NASDAQ:ERAS) in Q1 2026.
- Transaction value approximately $44.52 million.
- Paradigm's stake now 3.44% of its 13F AUM.
- Erasca share price $10.37 as of May 14, 2026.
- Erasca focuses on targeted oncology therapies for RAS/MAPK pathway.
Erasca stock (ERAS) faces mild downward pressure in the short-term (24-48h) due to fund selling, with a 1% impact expected.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHshort